



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/438,392	11/12/1999	TAKASHI AOYAMA	2312-105	9249

7590 01/15/2002

STEPHEN A. SAXE PH.D.
ROTHWELL, FIGG, ERNST & KURZ, P.C.
SUITE 701 EAST
555 13TH STREET NW
WASHINGTON, DC 20004

[REDACTED] EXAMINER

ZARA, JANE J

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1635

DATE MAILED: 01/15/2002

13

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/438,392	AOYAMA ET AL.
	Examiner Jane Zara	Art Unit 1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address.
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on ____.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-66 is/are pending in the application.
 4a) Of the above claim(s) 1-13 and 38-66 is/are withdrawn from consideration.
 5) Claim(s) ____ is/are allowed.
 6) Claim(s) 14-37 is/are rejected.
 7) Claim(s) ____ is/are objected to.
 8) Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 11) The proposed drawing correction filed on ____ is: a) approved b) disapproved by the Examiner.
 If approved, corrected drawings are required in reply to this Office action.
 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. ____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
 * See the attached detailed Office action for a list of the certified copies not received.
 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 a) The translation of the foreign language provisional application has been received.
 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s) _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>5 & 6</u> .	6) <input type="checkbox"/> Other: _____

File

Application/Control Number: 09/438,392

Page 2

Art Unit: 1635

DETAILED ACTION

Claims 1-66 are pending in the instant application.

Election/Restriction

Applicant's election with traverse of Group II in Paper No. 9 is acknowledged. The traversal is on the ground(s) that Groups II and III are not patentably distinct and that the nucleic acids and vectors of Group II are required to make the transgenics of Group III. This is not found persuasive because an examination of the very broad group of nucleic acids and vectors encompassed in Group II and the transgenics encompassed in Group III require consideration of very broad body of art as well as consideration of various issues including enablement, which considerations would not be coextensive for both groups, and hence to properly examine both Groups as presently claimed would be burdensome to the examiner.

The requirement is still deemed proper and is therefore made FINAL.

Claims 1-13 and 38-66 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 9.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Art Unit: 1635

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 26, 29, 31 and 32 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claims as presently drafted read on products of nature. The instant claims do not indicate the presence of "the hand of man". Drafting the claims to indicate that the nucleic acids are isolated would be remedial.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 15, 16, 27 and 28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 35 and 36 recite the limitation "said vector" in line 1. There is insufficient antecedent basis for this limitation in the claim.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to

Art Unit: 1635

make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 25 and 37 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The claims are drawn to a vector or nucleic acid comprising a regulatory domain of a glucocorticoid receptor or an estrogen receptor, and further comprising DNA encoding a DNA binding domain of bacterial repressor LexA fused to a G1090 promoter.

The following factors have been considered in determining that the specification does not enable the skilled artisan to make and/or use the invention claimed.

The amount of direction or guidance presented in the specification AND the presence or absence of working examples. Applicants have not provided guidance in the specification toward the method of making the synthetic promoter G1090. The specification provides a general outline comprising modifying a 35S promoter by fusing 4 copies of a G box to the 35S promoter. But no explicit description has been provided for the generation of this G1090 promoter so that one skilled in the art can make and use the G1090 promoter claimed. The specification fails to teach the nucleotide sequences comprising the G1090 promoter, nor has a deposit of the vector comprising this promoter been made. The specification as filed fails to provide the particular guidance required for one skilled in the art to make and use the instant promoter without undue experimentation.

Art Unit: 1635

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

Claims 14-24 and 26-36 are rejected under 35 U.S.C. 102(e) as being anticipated by Goff et al.

Goff et al teach vectors and isolated nucleic acids comprising a chemically inducible promoter, and further comprising a regulatory domain of a glucocorticoid and/or an estrogen receptor, a selectable marker such as an antibiotic or a herbicide resistant gene, a CaMV 35S promoter, the DNA-binding domain and upstream activating region of GAL4, DNA encoding the VP16 transactivating domain, the DNA binding domain of the LexA repressor, nucleic acids encoding luciferase and a gene of interest (See entire document, especially col. 1-3 and 9-14, and claims 1, 12 and 15).

Art Unit: 1635


Conclusion

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone numbers for the Group are (703) 308-4242 and (703) 305-3014. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(703) 306-5820**. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on (703) 308-0447. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (703) 305-3413. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JZ

January 9, 2002



ANDREW WANG
PRIMARY EXAMINER